Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of sintilimab in persistent, recurrent, or metastatic cervical cancer
ChiCTR1900021908Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in Cervical Cancer (CC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: overall response rate. Planned start May 2019; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1900021908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021908.